Finantzaketa

Ikertzaileren: Miguel Fernández de Sanmamed Gutiérrez

12 finantziazioak - 4.995.375€

2018az geroztik eskuragarri dauden datuak

2023

HUMANIZED-PDX MODELS TO DEVELOP IL-8/CXCR AND CD137 TARGETING THERAPIES TO OVERCOME RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS IN SKIN AND KIDNEY CANCER PATIENTS
1.250.000,00
Humanized-PDX models to support Treg targeting drugsdevelopm
150.013,00
NAV-22 CD25 imCORE Research agreement
68.000,00
Células dendríticas decross-priming como vacunas en una estrategia de inmunoterapia para cánceres renales y de urotelio.
1.007.600,00
Plataforma para la Identificación de TCR Específicos de Antígenos Tumorales para la Inmunoterapia de Tumores Sólidos (PITAGORAS)
474.228,00

2022

2021

IL-8/CXCR pathway modulation plus CD137 co-stimulation as a way to overcome resistance to PD-1/PD-L1 pathway blockade in melanoma and kidney cancer patients
300.000,00

2020

2018

Humanised-mouse models to implement immunotherapy of cancer
100.000,00